Efficacy of a Small-Molecule Inhibitor of Kras(G12D) in Immunocompetent Models of Pancreatic Cancer

Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS(G12D)) being the most common. Here, we tested the efficacy of a small-molecule KRAS(G12D) inhibitor, MRTX1133, in implantable and autochthonous PDAC mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemp, Samantha B., Cheng, Noah, Markosyan, Nune, Sor, Rina, Kim, Il-Kyu, Hallin, Jill, Shoush, Jason, Quinones, Liz, Brown, Natalie V., Bassett, Jared B., Joshi, Nikhil, Yuan, Salina, Smith, Molly, Vostrejs, William P., Perez-Vale, Kia Z., Kahn, Benjamin, Mo, Feiyan, Donahue, Timothy R., Radu, Caius G., Clendenin, Cynthia, Christensen, James G., Vonderheide, Robert H., Stanger, Ben Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Briefs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900321/
https://www.ncbi.nlm.nih.gov/pubmed/36472553
http://dx.doi.org/10.1158/2159-8290.CD-22-1066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900321/
https://www.ncbi.nlm.nih.gov/pubmed/36472553
http://dx.doi.org/10.1158/2159-8290.CD-22-1066

Ejemplares similares